Related Experiment Video
Updated: Jan 3, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Management of Locoregionally Advanced Melanoma
David T Pointer1, Jonathan S Zager1
1Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive, Tampa, FL, 33612; Department of Surgery, University of South Florida Morsani College of Medicine, 13220 USF Laurel Dr., Tampa, FL 33612.
Abstract:
Melanoma has a unique propensity for locoregional metastasis secondary to intralymphatic transit not seen in other cutaneous or soft tissue malignancies. Novel intralesional therapies using oncolytic immunotherapy exhibit increasing response rates with observed bystander effect. Intralesional modalities in combination with systemic immunotherapy are the subject of ongoing clinical trials. Regional therapy is used in isolated limb locoregional metastasis whereby chemotherapy is delivered to an isolated limb avoiding systemic side effects. Multimodal treatment strategy is imperative in the treatment of locoregionally advanced melanoma. One must be versed on these quickly evolving therapeutic options.
Insights
Advanced melanoma treatment involves unique intralymphatic metastasis strategies. Novel therapies combine intralesional oncolytic immunotherapy with systemic approaches and regional chemotherapy for improved outcomes in locoregionally advanced cases.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Melanoma exhibits unique locoregional metastasis via intralymphatic spread, distinct from other malignancies.
- Locoregionally advanced melanoma necessitates complex treatment strategies.
Purpose of the Study:
- To review evolving therapeutic options for locoregionally advanced melanoma.
- To highlight the role of novel intralesional and regional therapies.
Main Methods:
- Discussion of intralesional oncolytic immunotherapy and its bystander effect.
- Review of regional chemotherapy for isolated limb metastasis.
- Examination of combined intralesional and systemic immunotherapy clinical trials.
Main Results:
- Novel intralesional therapies show increasing response rates.
- Combination therapies are under active clinical investigation.
- Regional chemotherapy effectively targets isolated limb metastasis while minimizing systemic toxicity.
Conclusions:
- Multimodal treatment is crucial for managing locoregionally advanced melanoma.
- Emerging therapeutic options require continuous learning and adaptation by clinicians.
